US5266480A
(en)
*
|
1986-04-18 |
1993-11-30 |
Advanced Tissue Sciences, Inc. |
Three-dimensional skin culture system
|
US6048729A
(en)
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6544771B1
(en)
|
1987-12-11 |
2003-04-08 |
Cell Genesys, Inc. |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
US6001350A
(en)
*
|
1987-12-11 |
1999-12-14 |
Somatix Therapy Corp |
Genetic modification of endothelial cells
|
US6140111A
(en)
*
|
1987-12-11 |
2000-10-31 |
Whitehead Institute For Biomedical Research |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
US5716826A
(en)
*
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
US6133029A
(en)
*
|
1988-03-21 |
2000-10-17 |
Chiron Corporation |
Replication defective viral vectors for infecting human cells
|
ATE219519T1
(de)
*
|
1989-01-23 |
2002-07-15 |
Chiron Corp |
Rekombinanttherapien für infektionen und hyperproliferative störungen
|
ATE199398T1
(de)
*
|
1989-10-24 |
2001-03-15 |
Chiron Corp |
Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein
|
DE3941873A1
(de)
*
|
1989-12-19 |
1991-06-20 |
Jakob Dr Bodziony |
Hohlfaser mit der beschichtung von zellen, die mehrjaehrige implantation in arterien und venen ermoeglichen
|
DE4012079C2
(de)
*
|
1990-04-14 |
1997-11-06 |
Jakob Dr Bodziony |
Implantierbare Austausch- und Diffusionskammer
|
US5817491A
(en)
*
|
1990-09-21 |
1998-10-06 |
The Regents Of The University Of California |
VSV G pseusdotyped retroviral vectors
|
JP3249516B2
(ja)
*
|
1990-10-31 |
2002-01-21 |
ソマティクス セラピー コーポレイション |
遺伝子治療のためのレトロウイルスのベクター
|
FR2681609B1
(fr)
*
|
1991-09-24 |
1994-12-30 |
Centre Nat Rech Scient |
Lignees de cellules endotheliales cerebrales immortalisees, leur procede de preparation et leurs applications en tant que modele d'etude de la physiopathologie cerebrale.
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6063630A
(en)
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
PT101031B
(pt)
|
1991-11-05 |
2002-07-31 |
Transkaryotic Therapies Inc |
Processo para o fornecimento de proteinas por terapia genetica
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
US5891459A
(en)
|
1993-06-11 |
1999-04-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
|
US5591625A
(en)
*
|
1993-11-24 |
1997-01-07 |
Case Western Reserve University |
Transduced mesenchymal stem cells
|
US6150137A
(en)
|
1994-05-27 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Immunosuppressant target proteins
|
US5888814A
(en)
*
|
1994-06-06 |
1999-03-30 |
Chiron Corporation |
Recombinant host cells encoding TNF proteins
|
FR2726005B1
(fr)
*
|
1994-10-10 |
1997-01-03 |
Adim |
Lignees immortalisees de cellules endotheliales cerebrales et leurs applications au traitement de differents troubles ou maladies primaires et secondaires neurologiques ou psychiatriques
|
US6689757B1
(en)
|
1996-02-12 |
2004-02-10 |
M.L. Laboratories Plc |
Methods for vaccination and vaccines therefor
|
FR2746109B1
(fr)
|
1996-03-12 |
1998-04-17 |
Rhone Poulenc Rorer Sa |
Milieu pour la conservation de materiel biologique
|
US6723531B2
(en)
|
1996-04-05 |
2004-04-20 |
The Salk Institute For Biological Studies |
Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
US5980887A
(en)
*
|
1996-11-08 |
1999-11-09 |
St. Elizabeth's Medical Center Of Boston |
Methods for enhancing angiogenesis with endothelial progenitor cells
|
US6300488B1
(en)
|
1997-07-10 |
2001-10-09 |
The Salk Institute For Biological Studies |
Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
|
ATE258444T1
(de)
|
1998-03-13 |
2004-02-15 |
Univ British Columbia |
Therapeutische chemokine rezeptor antagonisten
|
CA2245224A1
(en)
|
1998-08-14 |
2000-02-14 |
Jiang-Hong Giong |
Chemokine receptor antagonists and chemotherapeutics
|
CA2305787A1
(en)
|
2000-05-09 |
2001-11-09 |
The University Of British Columbia |
Cxcr4 antagonist treatment of hematopoietic cells
|
US6333318B1
(en)
|
1998-05-14 |
2001-12-25 |
The Salk Institute For Biological Studies |
Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
US6093553A
(en)
*
|
1998-11-25 |
2000-07-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Immortalized brain endothelial cells
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
JP2002538167A
(ja)
|
1999-03-03 |
2002-11-12 |
バイオジェン インコーポレイテッド |
脂質の代謝および貯蔵を調節する方法
|
WO2000053743A1
(en)
|
1999-03-12 |
2000-09-14 |
Gpc Biotech, Inc. |
Methods and reagents for identifying synthetic genetic elements
|
US7504253B2
(en)
|
1999-06-11 |
2009-03-17 |
The Burnham Institute For Medical Research |
Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US8168178B2
(en)
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
CA2396062C
(en)
|
1999-12-30 |
2009-11-17 |
President And Fellows Of Harvard College |
Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or t cell subset activity by modulation of xbp-1 activity
|
US7378098B2
(en)
|
2000-04-12 |
2008-05-27 |
The University Of British Columbia |
CXC chemokine receptor 4 agonist peptides
|
US7368425B2
(en)
|
2006-03-24 |
2008-05-06 |
Chemokine Therapeutics Corp. |
Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
|
US20050059584A1
(en)
|
2002-08-16 |
2005-03-17 |
Ahmed Merzouk |
Novel chemokine mimetics synthesis and their use
|
EP1702983A3
(de)
|
2000-04-13 |
2007-01-10 |
Medical University of South Carolina |
Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
KR20030022094A
(ko)
|
2001-05-24 |
2003-03-15 |
(주)휴먼디엔에이테크놀로지 |
모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
|
EP2360251B1
(de)
|
2001-07-12 |
2016-09-28 |
University of Massachusetts |
In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
|
EP1900815B1
(de)
|
2001-07-12 |
2016-09-07 |
University of Massachusetts |
In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
|
EP1416943B1
(de)
|
2001-08-09 |
2012-05-02 |
Giuseppe Intini |
Gewebeimplantate und verfahren zur ihrer herstellung und verwendung
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
AU2002343475A1
(en)
|
2001-10-03 |
2003-04-14 |
Selective Genetics, Inc. |
Traversal of nucleic acid molecules through a fluid space and expression in repair cells
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
US7255874B1
(en)
|
2001-12-21 |
2007-08-14 |
Closure Medical Corporation |
Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
EP2258724A1
(de)
|
2002-11-21 |
2010-12-08 |
Celltech R & D, Inc. |
Modulierung von Immunantworten mittels multimeriserter Anti-CD83 Antikörper
|
CA2513251C
(en)
|
2003-01-14 |
2013-03-19 |
Dana-Farber Cancer Institute |
Cancer therapy sensitizer
|
DK1624936T3
(da)
|
2003-05-16 |
2010-03-15 |
Univ Laval |
CNS-chloridmodulering og anvendelser deraf
|
ES2864206T3
(es)
|
2003-06-02 |
2021-10-13 |
Univ Massachusetts |
Métodos y composiciones para mejorar la eficacia y la especificidad del ARNi
|
PL1633767T3
(pl)
|
2003-06-02 |
2019-07-31 |
University Of Massachusetts |
Sposoby i kompozycje do kontrolowania wydajności wyciszania rna
|
US7576052B2
(en)
|
2003-10-17 |
2009-08-18 |
Joslin Diabetes Center, Inc. |
Methods and compositions for modulating adipocyte function
|
AU2005222902B2
(en)
|
2004-03-12 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
CA2576193A1
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
DK2529619T3
(en)
|
2005-02-17 |
2016-01-11 |
Biogen Ma Inc |
Treatment of neurological disorders
|
EP1942948A4
(de)
|
2005-11-04 |
2010-03-03 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur hemmung der expression des nav1.8-genes
|
EP1945270B1
(de)
|
2005-11-09 |
2011-05-25 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen
|
CN101360826B
(zh)
|
2005-11-18 |
2014-04-30 |
格兰马克药品股份有限公司 |
抗α2整联蛋白抗体及它们的用途
|
CA2524619A1
(en)
|
2005-11-22 |
2007-05-22 |
Ottawa Health Research Institute |
Novel stem cells, nucleotide sequences and proteins therefrom
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
KR101547579B1
(ko)
|
2006-03-31 |
2015-08-27 |
알닐람 파마슈티칼스 인코포레이티드 |
Eg5 유전자의 발현을 억제하는 이본쇄 리보핵산
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
NZ587616A
(en)
|
2006-05-11 |
2012-03-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the pcsk9 gene
|
ATE528008T1
(de)
|
2006-05-19 |
2011-10-15 |
Alnylam Pharmaceuticals Inc |
Rnai-modulation von aha und ihre therapeutische verwendung
|
EP2192200B1
(de)
|
2006-05-22 |
2012-10-24 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der IKK-B-Gen-Expression
|
DK2034830T3
(da)
|
2006-05-25 |
2014-10-27 |
Biogen Idec Inc |
Anti-vla-1-antistof til behandling af slagtilfælde
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
EP2111553B1
(de)
|
2007-01-24 |
2018-09-19 |
Carnegie Mellon University |
Optische biosensoren
|
AU2008213999B2
(en)
|
2007-02-06 |
2014-04-17 |
Tai June Yoo |
Treatment and prevention of neurodegenerative diseases using gene therapy
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
WO2009004085A2
(en)
|
2007-07-05 |
2009-01-08 |
Novartis Ag |
Dsrna for treating viral infection
|
CA2707042A1
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor vii gene
|
KR101397407B1
(ko)
|
2008-03-05 |
2014-06-19 |
알닐람 파마슈티칼스 인코포레이티드 |
Eg5 및 VEGF 유전자의 발현을 억제하기 위한 조성물 및 방법
|
WO2009137613A2
(en)
|
2008-05-06 |
2009-11-12 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
EP3208337A1
(de)
|
2008-09-02 |
2017-08-23 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
|
US8546554B2
(en)
|
2008-09-25 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
|
AU2009307677C1
(en)
|
2008-10-20 |
2022-09-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
ES2940466T3
(es)
|
2008-11-10 |
2023-05-08 |
Alexion Pharma Inc |
Métodos y composiciones para tratar trastornos asociados al complemento
|
EP2373382B1
(de)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
|
MX2011008936A
(es)
|
2009-02-24 |
2011-09-21 |
Alexion Pharma Inc |
Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
NZ594995A
(en)
|
2009-03-12 |
2013-06-28 |
Alnylam Pharmaceuticals Inc |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
|
US9487756B2
(en)
|
2009-03-20 |
2016-11-08 |
Mesoblast, Inc. |
Production of reprogrammed pluripotent cells
|
WO2011005496A2
(en)
|
2009-06-22 |
2011-01-13 |
Massachusetts Eye & Ear Infirmary |
Islet1 (isl1) and hearing loss
|
EP2491145B1
(de)
|
2009-10-21 |
2016-03-09 |
Agios Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen für zellproliferationsbedingte erkrankungen
|
US9745589B2
(en)
|
2010-01-14 |
2017-08-29 |
Cornell University |
Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
|
EP3329924B1
(de)
|
2010-03-29 |
2021-05-05 |
Alnylam Pharmaceuticals, Inc. |
Dsrna-therapie für durch transthyretin (ttr) vermittelte augenamyloidose
|
SG185383A1
(en)
|
2010-04-30 |
2012-12-28 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
WO2012051301A1
(en)
|
2010-10-12 |
2012-04-19 |
President And Fellows Of Harvard College |
Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
|
US8815942B2
(en)
|
2010-10-20 |
2014-08-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
|
WO2012092299A1
(en)
|
2010-12-27 |
2012-07-05 |
Brown University |
Therapeutic and diagnostic methods involving biglycan and utrophin
|
WO2012109238A2
(en)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Methods for increasing immune responses using agents that directly bind to and activate ire-1
|
RU2631805C2
(ru)
|
2011-06-21 |
2017-09-26 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
|
EP2723351B1
(de)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
|
CN103998057A
(zh)
|
2011-09-15 |
2014-08-20 |
美国加州大学洛杉矶海滨分校医学中心的洛杉矶生物医学研究所 |
利用CotH的毛霉菌病的免疫疗法和诊断
|
CN104204192A
(zh)
|
2012-02-13 |
2014-12-10 |
加米达细胞有限公司 |
间充质干细胞调理的基质及其产生和使用方法
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
EP2946013A1
(de)
|
2013-01-16 |
2015-11-25 |
Iowa State University Research Foundation, Inc. |
Tiefes intronisches ziel zur spleisskorrektur des spinalen muskelatrophiegens
|
EP2769732A1
(de)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
|
WO2014128257A1
(en)
|
2013-02-22 |
2014-08-28 |
Sanofi |
Serpins: methods of therapeutic beta-cell regeneration and function
|
EP2851086A1
(de)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
|
BR112015023108A8
(pt)
|
2013-03-13 |
2018-01-23 |
Geneweave Biosciences Inc |
sistema de acondicionamento de célula bacteriana, método para acondicionamento de uma molécula de ácido nucléico repórter, composição, método para detectar uma presença ou uma ausência de uma célula bacteriana em uma amostra, vetor, método para detectar um transcrito alvo em uma célula, método para detectar a presença de uma célula bacteriana em uma amostra e kit.
|
WO2014197599A1
(en)
|
2013-06-04 |
2014-12-11 |
The Johns Hopkins University |
Peg-prom mediated surface expression of avidin/streptavidin
|
EP3004872B1
(de)
|
2013-06-04 |
2017-10-18 |
Virginia Commonwealth University |
Mda-9/syntenin-promotor zur abbildung und behandlung metastatischer krebszellen
|
WO2014197535A1
(en)
|
2013-06-04 |
2014-12-11 |
Virginia Commonwealth University |
Recombinant cancer therapeutic cytokine
|
EP3003022B1
(de)
|
2013-06-04 |
2017-11-22 |
Virginia Commonwealth University |
Verwendung eines trunkierten ccn1-promotors für krebsdiagnostik, therapeutika und theranostika
|
US10166300B2
(en)
|
2013-06-04 |
2019-01-01 |
Virginia Commonwealth University |
Tripartite cancer theranostic nucleic acid constructs
|
DK3049521T3
(en)
|
2013-09-25 |
2019-04-23 |
Univ Cornell |
Compounds for inducing antitumor immunity and methods thereof
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
EP3191139B1
(de)
|
2014-07-24 |
2020-10-07 |
Massachusetts Eye & Ear Infirmary |
Rpgr-gentherapie für retinitis pigmentosa
|
US10632151B2
(en)
|
2015-01-22 |
2020-04-28 |
University Of Massachusetts |
Cancer immunotherapy
|
WO2016123454A1
(en)
|
2015-01-29 |
2016-08-04 |
Board Of Trustees Of Miching State University |
Cryptic polypeptides and uses thereof
|
RS60668B1
(sr)
|
2015-03-06 |
2020-09-30 |
Massachusetts Eye & Ear Infirmary |
Terapije augmentacije gena za naslednu degeneraciju retine uzrokovanu mutacijama u genu prpf31
|
EP3735982A1
(de)
|
2015-03-10 |
2020-11-11 |
The University of Massachusetts |
Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
|
US20180104331A1
(en)
|
2015-05-11 |
2018-04-19 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
EP3294332A4
(de)
|
2015-05-14 |
2018-12-26 |
Joslin Diabetes Center, Inc. |
Retinolbindendes protein 3 (rbp3) als schutzfaktor bei nicht diabetischer netzhautdegeneration
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
WO2017066796A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
EP3377086B1
(de)
|
2015-11-19 |
2024-05-01 |
The Brigham and Women's Hospital, Inc. |
Lymphozytenantigen cd5-like(cd5l)-interleukin 12b (p40)-heterodimere in der immunität
|
EP3299460A1
(de)
|
2016-09-26 |
2018-03-28 |
Johann Wolfgang Goethe-Universität Frankfurt am Main |
Neuartige verbindungen und verfahren zur modulation der ubiquitinierung
|
EP3532638A4
(de)
|
2016-10-31 |
2020-07-29 |
University of Massachusetts |
Targeting von microrna-101-3p in der krebstherapie
|
US11795201B2
(en)
|
2017-04-14 |
2023-10-24 |
University Of Massachusetts |
Brown fat-selective adipokines
|
WO2019005897A1
(en)
|
2017-06-28 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
DK3658184T3
(da)
|
2017-07-27 |
2023-11-27 |
Alexion Pharma Inc |
Højkoncentrerede anti-c5-antistofformuleringer
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
CA3102182A1
(en)
|
2018-06-01 |
2019-12-05 |
Sanofi |
Combination therapy for treating hepatitis b virus infection
|
ES2973946T3
(es)
|
2018-07-19 |
2024-06-25 |
Regeneron Pharma |
Receptores de antígenos quiméricos con especificidad por el BCMA y usos de los mismos
|
CA3117539A1
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Ny-eso-1 t cell receptors and methods of use thereof
|
WO2020120649A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
|
JP2022515451A
(ja)
|
2018-12-27 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
アシネトバクター・バウマンニの検出のための、非複製的形質導入粒子及び形質導入粒子に基づくレポーター系
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
IT201900007060A1
(it)
|
2019-05-21 |
2020-11-21 |
St Superiore Di Sanita |
Cellule tumorali ingegnerizzate e loro usi
|
IT201900012540A1
(it)
|
2019-07-22 |
2021-01-22 |
Humanitas Mirasole Spa |
Inibitori di CHI3L1 e loro usi
|
US20220281994A1
(en)
|
2019-07-24 |
2022-09-08 |
Regeneron Pharmaceuticals, Inc. |
Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof
|
AU2020328507A1
(en)
|
2019-08-12 |
2022-03-17 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
US20230028476A1
(en)
|
2019-12-03 |
2023-01-26 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use in treating hepatitis b infection
|
IL293450A
(en)
|
2019-12-03 |
2022-07-01 |
Evotec Int Gmbh |
Interferon-related antigen-binding proteins and uses thereof
|
WO2021136752A1
(en)
|
2019-12-31 |
2021-07-08 |
F. Hoffmann-La Roche Ag |
Quantitative pcr screening of inducible prophage from bacterial isolates
|
IL294988A
(en)
|
2020-01-24 |
2022-09-01 |
Regeneron Pharma |
Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
|
WO2021217024A1
(en)
|
2020-04-24 |
2021-10-28 |
Millennium Pharmaceuticals, Inc. |
Anti-cd19 antibodies and uses thereof
|
BR112022021871A2
(pt)
|
2020-05-05 |
2023-01-31 |
Regeneron Pharma |
Polipeptídeo car, composição, ácido nucleico, célula imune, método para tratar um tumor, e, banco de células
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
KR20230069961A
(ko)
|
2020-09-14 |
2023-05-19 |
보르 바이오파마 인크. |
Cd33에 대한 단일 도메인 항체
|
CA3205574A1
(en)
|
2020-12-18 |
2022-06-23 |
Momenta Pharmaceuticals, Inc. |
Antibodies against integrin alpha 11 beta 1
|
EP4320149A1
(de)
|
2021-04-09 |
2024-02-14 |
Takeda Pharmaceutical Company Limited |
Gegen komplementfaktor d gerichtete antikörper und verwendungen davon
|
CA3216770A1
(en)
|
2021-04-26 |
2022-11-03 |
Tomoki Yoshihara |
Anti-clec12a antibodies and uses thereof
|
WO2022232035A1
(en)
|
2021-04-26 |
2022-11-03 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2 antibodies and uses thereof
|
AU2022271212A1
(en)
|
2021-05-04 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
JP2024521958A
(ja)
|
2021-06-09 |
2024-06-04 |
エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
コロナウイルス感染の処置又は予防のための使用のためのインターフェロン会合抗原結合性タンパク質
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
WO2023057946A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
IL311837A
(en)
|
2021-10-20 |
2024-05-01 |
Takeda Pharmaceuticals Co |
BCMA designated preparations and methods for their use
|
WO2023201238A1
(en)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
Binding agents and methods of use thereof
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
WO2024126289A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
|
WO2024126294A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
|
WO2024126293A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
|